Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases

Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases

Relapse remains challenging in the treatment of metastatic cancers. More than 50% of human cancers harbor mutant p53 (mp53) as a cancer-specific target. We present the spontaneously metastasizing tumor model Ag104A to advance mp53-specific T cell receptor engineered T cell therapy (TCR-therapy). We...

Full description

Saved in:
Bibliographic Details
Main Authors: Vasiliki Anastasopoulou, Hans Schreiber, Ching-En Lee, Kazuma Kiyotani, Leo Hansmann, Yusuke Nakamura, Matthias Leisegang, Steven P. Wolf
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:OncoImmunology
Subjects:
Adoptive cell transfer
metastatic tumor model
mutant p53
neoantigen
TCR-therapy
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2025.2514041
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2025.2514041

Similar Items